Sovaldi (Sofosbuvir) Hepatitis C Drug Information

Sovaldi (sofosbuvir) inorodzwa nucleotide polymerase inhibitor class drug inoshandiswa mukubatanidza mushonga untiviral mushonga wokurapa hepatitis C (HCV) . Sovaldi inoshanda nekuvhara enzyme inoshandiswa neHCV kudzokorora RNA yayo, inopedza kukanganisa danho muhutachiona hwehutachiona.

Sovaldi yakabvumirwa munaDisemba 2013 neU.S. Food and Drug Administration (FDA) iyo inoshandiswa kune vanhu vakuru makore gumi nemana kana kupfuura neHCV genotypes 1, 2, 3 uye 4 utachiona, kusanganisira avo vane hepatocellular carcinoma (iyo yakawanda inowanzo muropa wekenza) uye kune vanhu vane HIV / HCV pamwe-kutapukirwa.

Sovaldi inogamuchirwa kuti ishandiswe mune zvekare isati isatorwa (varwere-naïve) varwere, pamwe chete nevaya vasina rutivi kana kusina mhinduro kune hutano hweHCV yapfuura.

Kuongororwa kwechipatara kwakaratidza kuti chirwere chekurapa-naïve varwere muSovaldi-based regimen iri pakati pe 82% uye 96%.

Dosage

Rimwe piritsi ye 400 mg inotorwa zuva nezuva kana kuti isina zvokudya. Sofuradi mahwendefa akachena uye mafirimu-akavezwa, ane "GSI" yakaiswa pamativi maviri uye "7977" pane imwe.

Kunyora Zvikurudzira

Sovaldi inorayirwa kuti ishandiswe mukurapa pamwe ne ribavirin ; pamwe chete pegylated interferon (peg-interferon) + ribavirin; kana naDadlinza (daclatasvir) . Sovaldi haifaniri kushandiswa se monotherapy.

Izvi zvinotevera zvirongwa zvekurapa zvinokurudzirwa:

Kune varwere vane genotype 1 avo vasina kukodzera kubereferenon kana interferon-kusagadzikana, zvinokurudzirwa kuti kusanganiswa kweSovaldi + ribavirin kunyoreswe kwemavhiki makumi maviri nemana.

Kune chero chirwere chiri kumirira kuwedzerwa kwechiropa, mishonga inorongwa pamusoro apa inofanira kurongerwa kwemavhiki makumi maviri nemashanu kana kusvika kushandiswa kwaitwa, chero chipi chinouya pakutanga.

Nharaunda Dzakabatana

Zvipembenene zvinowanzobatanidzwa nekushandiswa kweSovaldi + ribavirin (kureva, zvichiitika mu20% kana pasi pevarwere) ndezvi:

Zvipembenene zvinowanzoonekwa kune varwere vachishandisa Sovaldi + ribavirin + peg-interferon ndei:

Kunze kwekushaya ropa uye neutropenia, ruzhinji rwemigumisiro inobatanidzwa neSovaldi kushandiswa inofungidzirwa zvinyoro kana nguva (Chikoro 1).

Mukutsvakurudza kwekliniki, 1% kana kuti pasi pevarwere vari muSovaldi + ribavirin vakagumisa kurapwa kwenguva pfupi nekuda kwekusagadzikana migumisiro. Chiitiko chacho chakawedzera kusvika 11% kune varwere veSovaldi + ribavirin + peg-interferon.

Kubatana Kwemishonga

Izvi zvinotevera zvinofanirawo kudziviswa kana uchishandisa Sovaldi:

Kune varwere vane HIV , Sovaldi haifaniri kubatanidzwa pamwe chete neAptivus (tipranavir) kana Norvir (ritonavir) sezvo idzi protease inhibitor yechirwere chetachiona chetachiona chinogona kuderedza serum concentration yeSovaldi.

Contraindications

Sovaldi inopesana kuti inoshandiswa panguva yekudzivirira kana kuti varume avo vane vavakadzi vane pamuviri semakororo emhuka vakaratidza kuti kune ngozi inogona kuitika yekuzvarwa kwepabonde kana kufa kwekufa.

Zvinokurudzirwa kuti vakadzi vose vane makore anobereka vana vanofanira kuongororwa mwedzi wega wega nekuda kwepamuviri panguva yekurapa. Inokurudzirwawo kuti murwere nemurume wake mukomana vagoverwa maitiro maviri asingaiti mahomoni ekudzivirira kubata pamuviri uye kuti anoshandiswa panguva yekurapa uye kwemwedzi mitanhatu gare gare.

Kunobva:

Manns, M. uye Cornberg, M. "Sofosbuvir: mbambo yekupedzisira mubhokisi rehepatitis C?" Lancet. March 15, 2013; 13 (5): 378-379.